In an 80-year-old man with an E. coli urinary tract infection and a measured GFR of 51 mL/min, what is the appropriate dose of weropeneum?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 15, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Meropenem Dosing for E. coli UTI in 80-Year-Old with GFR 51 mL/min

For this 80-year-old man with E. coli urinary tract infection and GFR 51 mL/min, meropenem should be dosed at 500 mg IV every 12 hours (for complicated skin/soft tissue infections) or 1 gram IV every 12 hours (for intra-abdominal infections), based on the FDA-approved renal dosing adjustment for creatinine clearance 26-50 mL/min. 1

Renal Dose Adjustment Algorithm

The FDA prescribing information provides clear guidance for meropenem dosing in renal impairment 1:

  • GFR >50 mL/min: Standard dose (500 mg or 1 gram depending on infection) every 8 hours
  • GFR 26-50 mL/min: Recommended dose every 12 hours (your patient falls here)
  • GFR 10-25 mL/min: One-half recommended dose every 12 hours
  • GFR <10 mL/min: One-half recommended dose every 24 hours

Specific Dosing for UTI Context

For urinary tract infections specifically, the appropriate meropenem dose depends on infection severity 1:

  • If treating as complicated UTI/pyelonephritis: Use 1 gram IV every 12 hours (adjusted from standard 1 gram every 8 hours)
  • If Pseudomonas aeruginosa is suspected or confirmed: The standard recommendation is 1 gram every 8 hours, which should be adjusted to 1 gram every 12 hours for GFR 26-50 mL/min 1

Each dose should be administered as an IV infusion over 15-30 minutes 1.

Critical Considerations for This Patient

Age-related factors: At 80 years old, this patient likely has age-related decline in renal function beyond the measured GFR 2. The Cockcroft-Gault formula (which the FDA dosing is based on) accounts for age, but actual drug clearance may be further reduced 2.

E. coli susceptibility: While E. coli is typically susceptible to carbapenems, local resistance patterns should guide therapy 3. For ESBL-producing E. coli causing UTI, meropenem remains an excellent choice 3.

Monitoring requirements: In patients with renal dysfunction, thrombocytopenia has been observed with meropenem 1. Monitor complete blood counts during therapy, particularly if treatment extends beyond 7-10 days.

Common Pitfalls to Avoid

  • Do not use standard dosing: Failure to adjust for renal function risks drug accumulation and increased adverse effects, particularly CNS toxicity including seizures 1
  • Verify creatinine clearance calculation: Ensure GFR/CrCl was calculated using Cockcroft-Gault formula, as this is what FDA dosing tables are based on 1, 2
  • Avoid underdosing: Do not reduce the individual dose amount when GFR is 26-50 mL/min—only extend the interval to every 12 hours 1
  • Consider drug interactions: If the patient is on valproic acid or divalproex sodium, meropenem significantly reduces valproic acid levels and increases seizure risk 1

Alternative Considerations

If meropenem is being considered for a simple E. coli cystitis (which would be unusual), other agents with better oral bioavailability and simpler dosing would be more appropriate, such as nitrofurantoin or fosfomycin 4, 3. However, if this represents complicated UTI, pyelonephritis, or bacteremia with urinary source, the parenteral carbapenem approach is justified 3.

Related Questions

What is the recommended treatment for a urinary tract infection caused by Escherichia coli (E. coli) with a urine culture result showing greater than 100,000 Colony-Forming Units per milliliter (CFU/mL)?
What is the recommended treatment for a urinary tract infection caused by Escherichia coli (E. coli) with a urine culture result showing greater than 100,000 colony-forming units per milliliter (CFU/mL)?
Do we treat a urinary tract infection with 10,000 to 49,000 colony-forming units (CFU) of Escherichia coli per milliliter (mL)?
What is the next step in managing a 25-year-old woman with recurrent Escherichia coli (E. coli) urinary tract infections (UTIs) presenting with urgency and frequency, but no fever?
What is the appropriate treatment for a patient with a urinary tract infection (UTI) caused by Escherichia coli (E. coli), given the antimicrobial susceptibility results?
Can Lexapro (escitalopram) and buspirone be prescribed together safely in adults, and what are the recommended dosing and monitoring guidelines?
What is the appropriate management of vitamin D deficiency in an otherwise healthy adult?
In a patient with ascites and bilateral lower‑extremity edema, should hypertensive heart disease‑related heart failure (NYHA class III) be considered as a differential diagnosis?
What is the recommended acute and chronic management for an adult with gout, including first‑line medications, dosing, and indications for urate‑lowering therapy?
Which investigations are indicated for suspected irritable bowel syndrome, and how do red‑flag features such as age > 50, unexplained weight loss, rectal bleeding, anemia, persistent diarrhea, fever, or a family history of inflammatory bowel disease or colorectal cancer modify the work‑up?
How should an asymptomatic adult (20‑40 years) with radiologically isolated syndrome be evaluated, risk‑stratified, and managed, including recommendations for disease‑modifying therapy and follow‑up?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.